REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven ratings ...
Chardan Capital reaffirmed their buy rating on shares of REGENXBIO (NASDAQ:RGNX – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. They currently have a $52.00 ...
Regenxbio (RGNX) stock gains and Solid Biosciences (SLDB) stock falls after Sarepta Therapeutics' (SRPT) safety update on ...
Regenxbio's RGX-202 gene therapy shows promising results in Duchenne muscular dystrophy, with high microdystrophin levels and ...
US gene therapy company Regenxbio has reported new, positive interim data from two additional patients in the Phase I/II ...
REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of ...
REGENXBIO Inc. (Nasdaq: RGNX) today reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE® trial of RGX-202, a differentiated ...
(RTTNews) - REGENXBIO (RGNX) reported new, positive interim data from two additional patients in the Phase I/II portion of the AFFINITY DUCHENNE trial of RGX-202, a differentiated investigational ...
Stocktwits on MSN4d
Sarepta Therapeutics Stock Has A Nightmarish Week After DMD Patient Death, But Retail And Analysts Aren't Giving UpShares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...
After hours: March 21 at 7:44:36 PM EDT Loading Chart for RGNX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback